ArticleMolecular medicine reports2017
MicroRNA expression signature and the therapeutic effect of the microRNA‑21 antagomir in hypertrophic scarring.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- An Overview of the Mechanisms of Fractional COLasers in medical science · 2026Review
- Circ_0011446 Regulates Intramuscular Adipocyte Differentiation in Goats via the miR-27a-5p/FAM49B Axis.International journal of molecular sciences · 2025Article
- Article
- Non-coding RNAs as skin disease biomarkers, molecular signatures, and therapeutic targets.Human genetics · 2024Review
- Reviewing the Regulators of COL1A1.International journal of molecular sciences · 2023Review
- Non-coding RNA and cholesteatoma.Laryngoscope investigative otolaryngology · 2022Review
- The Emerging Therapeutic Targets for Scar Management: Genetic and Epigenetic Landscapes.Skin pharmacology and physiology · 2022Review
- Effect of miRNA-136-targeted regulation of FGFR1 on proliferation and apoptosis of triple-negative breast cancer cells.American journal of translational research · 2021Article
- Advances in scarless foetal wound healing and prospects for scar reduction in adults.Cell proliferation · 2020Review
- The Effects of the Transforming Growth Factor-β1 (TGF-β1) Signaling Pathway on Cell Proliferation and Cell Migration are Mediated by Ubiquitin Specific Protease 4 (USP4) in Hypertrophic Scar Tissue and Primary Fibroblast Cultures.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Decreased expression of microRNA-145 promotes the biological functions of fibroblasts in hypertrophic scar tissues by upregulating the expression of transcription factor SOX-9.Experimental and therapeutic medicine · 2019Article
- Article
- Advancements in Regenerative Strategies Through the Continuum of Burn Care.Frontiers in pharmacology · 2018Review
- MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.Molecular diagnosis & therapy · 2017Review
- Is the future scarless? - Fibroblasts as targets for scarless wound healing: a narrative review.Scars, burns & healingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic scars (HS) area fibroproliferative disorder of the skin, which causes aesthetic and functional impairment. However, the molecular pathogenesis of this disease remains largely unknown and currently no efficient treatment exists. MicroRNAs (miRNAs) are involved in a variety of pathophysiological processes, however the role of miRNAs in HS development remains unclear. To investigate the miRNA expression signature of HS, microarray analysis was performed and 152 miRNAs were observed to be differentially expressed in HS tissue compared with normal skin tissues. Of the miRNAs identified, miRNA‑21 (miR‑21) was significantly increased in HS tissues and hypertrophic scar fibroblasts (HSFBs) as determined by reverse transcription‑quantitative polymerase chain reaction analysis. It was also observed that, when miR‑21 in HSFBs was blocked through use of an antagomir, the phenotype of fibrotic fibroblasts in vitro was reversed, as demonstrated by growth inhibition, induction of apoptosis and suppressed expression of fibrosis‑associated genes collagen type I α 1 chain (COL1A1), COL1A2 and fibronectin. Furthermore, miR‑21 antagomir administration significantly reduced the severity of HS formation and decreased collagen deposition in a rabbit ear HS model. The total scar area and scar elevation index were calculated and were demonstrated to be significantly decreased in the treatment group compared with control rabbits. These results indicated that the miR‑21 antagomir has a therapeutic effect on HS and suggests that targeting miRNAs may be a successful and novel therapeutic strategy in the treatment of fibrotic diseases that are difficult to treat with existing methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.